Examkin

Soru

Zorluk: ZorPharmacologic Interventions

An independent 68-year-old resident of a senior living community presents to the ambulatory care clinic reporting two days of painful urination and severe urinary urgency. She notes lower pelvic pressure but denies fevers, chills, vaginal discharge, or back pain. Her medical history is significant for seropositive rheumatoid arthritis, hypertension, and stage 4 chronic kidney disease secondary to hypertensive nephrosclerosis. Her daily medications include amlodipine and folic acid, and she takes methotrexate once weekly. Vital signs are within normal limits. Physical examination reveals mild suprapubic tenderness without costovertebral angle tenderness.

Laboratory results:
Serum creatinine: 2.3 mg/dL
Estimated GFR: 24 mL/min/1.73 m²

Urinalysis:
Appearance: Cloudy
Specific gravity: 1.018
pH: 6.5
Leukocyte esterase: Positive
Nitrite: Negative
Protein: Trace
WBC: 25-30/hpf
RBC: 1-2/hpf
Bacteria: Moderate

Which of the following is the most appropriate next step in pharmacologic management?

  1. Prescribe oral cephalexinCevap
  2. B
    Prescribe oral nitrofurantoin
  3. C
    Prescribe oral trimethoprim-sulfamethoxazole
  4. D
    Prescribe oral ciprofloxacin
  5. E
    Withhold antibiotics until urine culture results finalize

Cevap

Prescribe oral cephalexin
The correct answer is to prescribe oral cephalexin. The patient presents with classic symptoms of acute uncomplicated cystitis supported by urinalysis demonstrating pyuria. Standard first-line empiric treatments for uncomplicated cystitis include nitrofurantoin, trimethoprim-sulfamethoxazole (TMP-SMX), and fosfomycin. However, this patient's complex medical history restricts standard choices. Nitrofurantoin is contraindicated in patients with an estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m² because it will not achieve adequate therapeutic concentrations in the bladder and poses a higher risk of systemic toxicity. TMP-SMX is absolutely contraindicated due to her concurrent use of methotrexate; both medications act as folate antagonists, and their co-administration can precipitate profound, life-threatening pancytopenia. Consequently, an alternative second-line agent must be used. Oral beta-lactams, such as cephalexin, cefpodoxime, or amoxicillin-clavulanate, are safe and effective alternatives in this setting.

Adım Adım Çözüm

1
Diagnose the clinical condition
The patient has acute uncomplicated cystitis based on dysuria, urgency, suprapubic pain, and pyuria.
Establishing the diagnosis dictates the initial choice of empiric antimicrobial therapy.
2
Evaluate first-line therapies against patient comorbidities
Nitrofurantoin is ruled out due to stage 4 CKD (eGFR 24 mL/min). Trimethoprim-sulfamethoxazole is ruled out due to concurrent methotrexate use.
First-line therapies carry absolute or relative contraindications in specific medically complex populations.
3
Select the best alternative agent
Oral cephalexin (or another appropriate beta-lactam) is selected.
Beta-lactams are safe in CKD (with appropriate dose adjustment) and do not have major pharmacodynamic interactions with methotrexate.

Anahtar Kavram

Empiric antimicrobial selection must account for renal function and potentially fatal drug-drug interactions, such as the synergistic bone marrow suppression caused by co-administration of methotrexate and trimethoprim-sulfamethoxazole.
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Pharmacologic Interventions

Bu konudan daha fazla soru